Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
Learn more: For first time in 40 years, cure for acute leukemia within reach
The Latest on: Acute myeloid leukemia
[google_news title=”” keyword=”acute myeloid leukemia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Acute myeloid leukemia
- AML patients at the extremes of older age derive benefit from VEN-HMA regimenon May 9, 2024 at 10:50 pm
Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia . For roughly a quarter of patients, this ...
- Standard blood cancer treatment reveals positive results in those over 80, study findson May 9, 2024 at 9:12 pm
The standard treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, a study published Thursday in Blood Neoplasia finds. The treatment can extend survival for about 25% ...
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlightson May 9, 2024 at 9:05 am
First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE ...
- A New Kid on the Block of Therapy for Acute Myeloid Leukemiaon May 9, 2024 at 5:02 am
Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.
- Red carpet with a cause: This fashion show fundraiser helps kids with canceron May 9, 2024 at 1:12 am
This fashion show fundraiser has provided tens of thousands of dollars to children with cancer. Now it's growing bigger than ever.
- Leukemia Relapse Could Be Prevented by Disrupting Immune Signaling Mechanismon May 8, 2024 at 6:13 pm
New study suggests that a subset of cancers with high levels of PI3KR5 expression might respond better to an experimental immunotherapy.
- Researchers discover new target for potential leukemia therapyon May 8, 2024 at 8:00 am
A team of Dana-Farber Cancer Institute investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival. The study provides both ...
- Dana-Farber researchers discover new target for potential leukemia therapyon May 7, 2024 at 5:00 pm
A team of Dana-Farber Cancer Institute investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival. The study provides both ...
- New target for potential leukemia therapyon May 7, 2024 at 5:00 pm
The study provides both mechanistic and preclinical evidence supporting the rapid initiation of clinical trials for patients with acute myeloid leukemia (AML) to test an existing medicine that ...
- GlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary Endpointon May 6, 2024 at 3:18 am
By Adriano Marchese GlycoMimetics shares were sharply lower in premarket trading on Monday after the company said its drug to treat a form of acute ...
via Bing News